New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 15, 2014
14:22 EDTAGIOAgios announces new data from ongoing Phase 1 study of AG-221
Agios Pharmaceuticals announced new clinical data from the ongoing Phase 1 study of AG-221, which includes 35 patients with IDH2 mutant positive hematologic malignancies. These data confirm and build upon previously presented data on AG-221’s clinical activity, safety profile and unique mechanism of action. The data were presented today in a late-breaker oral presentation at the 19th Congress of the European Hematology Association, EHA, in Milan, Italy by Stéphane de Botton, M.D., the principal investigator at the Institut de Cancérologie Gustave Roussy, Villejuif, France.
News For AGIO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 26, 2015
08:14 EDTAGIOBoston Biotech Conferences to hold a conference
Subscribe for More Information
May 21, 2015
08:08 EDTAGIOAgios Pharmaceuticals to present data at 20th Congress of EHA
Subscribe for More Information
May 19, 2015
08:57 EDTAGIOLeerink biotech analyst holds an analyst/industry conference call
Subscribe for More Information
May 18, 2015
07:37 EDTAGIOAgios Pharmaceuticals AG-120 granted FDA Fast Track designation
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use